Vision‑Restoring Chip Implanted in First Stargardt Patient as Company Eyes Future Brain‑Computer Interfaces

Science Corporation announced that it has successfully implanted its experimental vision‑restoring chip in a patient diagnosed with Stargardt disease, marking the company's inaugural use of the device in a human subject.

Stargardt disease is an inherited form of macular degeneration that progressively erodes central vision, often leading to legal blindness. Current therapeutic options are limited to low‑vision aids, leaving a substantial unmet need for interventions that can restore sight.

The implanted device, developed under the company’s PRIMA program, converts visual information captured by a miniature camera into electrical signals that stimulate the remaining retinal cells, allowing the brain to interpret visual cues. While the technology is still in early stages, the procedure demonstrates that the system can be surgically placed and activated without immediate complications.

Speaking at the recent TechCrunch Disrupt conference, Max Hodak—formerly the president and co‑founder of Neuralink— explained that the retinal implant serves as a proof‑of‑concept for the broader brain‑computer interface (BCI) roadmap the company is pursuing. Hodak highlighted that mastering the interface between external hardware and neural tissue in the eye could inform future efforts to link computers directly with other regions of the brain.

The implantation is being closely watched by both the ophthalmic and neurotechnology communities, as it suggests a viable path toward restoring functional vision for people with degenerative retinal conditions. If subsequent trials confirm safety and efficacy, the approach could expand to address age‑related macular degeneration and other forms of blindness.

Science Corporation indicated that it will begin enrolling additional participants in a series of clinical studies aimed at gathering longer‑term data on visual outcomes and device durability. Regulatory review and further validation will be required before the technology can move toward commercial availability, but the successful first surgery signals a tangible step forward in the convergence of vision restoration and brain‑computer interfacing.